Screener
ImmunityBio, Inc. IBRX Product revenue, net — Total Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:37 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326110-26-000059
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Revenue | ||
| Product revenue, net | $44,167 | $16,509 |
| Other revenues | 39 | 8 |
| Total revenue | 44,206 | 16,517 |
| Operating costs and expenses | ||
| Cost of sales | 238 | 58 |
| Research and development | 64,770 | 45,976 |
| Research and development – related parties | 3,219 | 2,258 |
ITEM 1. FINANCIAL STATEMENTS.
FAQ
- What is ImmunityBio, Inc.'s product revenue, net — total revenue?
- ImmunityBio, Inc. (IBRX) reported product revenue, net — total revenue of $44.17M in Q1 2026.
- How has ImmunityBio, Inc.'s product revenue, net — total revenue changed year-over-year?
- ImmunityBio, Inc.'s product revenue, net — total revenue increased by 167.5% year-over-year, from $16.51M to $44.17M.
- What does product revenue, net — total revenue mean?
- This metric represents the total net revenue generated specifically from the sale of commercialized pharmaceutical or biotechnology products. It excludes non-product income such as licensing fees, research grants, or collaborative development payments. This figure serves as a primary indicator of the company's transition from a clinical-stage research entity to a commercial-stage enterprise.
Ask your AI about ImmunityBio, Inc.'s product revenue, net — total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude